AlphaFold predicted structure
CDC42BPB · Q9Y5S2

Mean pLDDT
75.8/ 100
Confident
1,711 residues
Confidence breakdown
- Very high(≥ 90)31%
- Confident(70–90)44%
- Low(50–70)10%
- Very low(< 50)15%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
CDC42 binding protein kinase beta
Annotations refreshed 1 month ago.
Diagnostic Grade (Green)
Fetal anomalies
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedEarly onset or syndromic epilepsy
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedIntellectual disability
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedDDG2P
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownChilton-Okur-Chung neurodevelopmental syndrome
neurodegenerative disease
hereditary disease
neurodevelopmental disorder
autism spectrum disorder
brain cancer
nervous system cancer
placenta praevia
Parkinson disease
peripheral nervous system disorder
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Serine/threonine-protein kinase MRCK beta
Serine/threonine-protein kinase which is an important downstream effector of CDC42 and plays a role in the regulation of cytoskeleton reorganization and cell migration. Regulates actin cytoskeletal reorganization via phosphorylation of PPP1R12C and MYL9/MLC2 (PubMed:21457715, PubMed:21949762). In concert with MYO18A and LURAP1, is involved in modulating lamellar actomyosin retrograde flow that is crucial to cell protrusion and migration (PubMed:18854160). Phosphorylates PPP1R12A (PubMed:21457715). In concert with FAM89B/LRAP25 mediates the targeting of LIMK1 to the lamellipodium resulting in its activation and subsequent phosphorylation of CFL1 which is important for lamellipodial F-actin regulation (By similarity)
CDC42BPB · Q9Y5S2

Mean pLDDT
75.8/ 100
Confident
1,711 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0